Brain Connectivity-Targeted tACS Trial in Early AD

V2, Crosslink

🧫

Brain Connectivity-Targeted tACS Trial in Early AD

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 50% ✓ SciDEX ID: experiment-exp-wiki-brain-connectivity-t

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Brain Connectivity-Targeted tACS Trial in Early AD ## Background and Rationale Alzheimer's disease (AD) represents a complex neurodegenerative disorder characterized not only by the hallmark pathological accumulations of amyloid-beta plaques and tau neurofibrillary tangles, but increasingly recognized for its profound disruption of neural network function. Emerging evidence from resting-state functional magnetic resonance imaging (rs-fMRI) studies reveals that early-stage AD is marked by aberr

METHODOLOGY NOTES

## PROTOCOL **Phase 1: Pre-intervention Characterization and Baseline Assessment (Weeks -4 to 0)** Recruit a cohort of 48 transgenic AD model mice (APP/PS1 or 5xFAD line, 5-6 months old, n=24 intervention, n=24 controls) with confirmed early-stage amyloid-beta pathology validated via in vivo two-photon microscopy and plasma biomarkers (phospho-tau181, phospho-tau217). Perform comprehensive baseline neurophysiological profiling including: (1) resting-state functional magnetic resonance imaging (rs-fMRI) at 9.4T with 200 µm isotropic resolution to map default mode network (DMN) connectivity patterns, (2) electrophysiological recordings from prefrontal cortex (PFC), hippocampal CA3-CA1, and posterior cingulate cortex (PCC) using 32-channel silicon probes to characterize baseline oscillatory dynamics and cross-regional coherence in theta (4-12 Hz), gamma (30-100 Hz), and sleep spindle (10-16 Hz) bands, (3) Morris water maze testing for spatial reference memory (acquisition: 4 days, 6 tri

▸Metadatasource: {'pmid': '39402379', 'type': 'paper', 'e

source	{'pmid': '39402379', 'type': 'paper', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.896439Z'}
summary	# Brain Connectivity-Targeted tACS Trial in Early AD ## Background and Rationale Alzheimer's disease (AD) represents a complex neurodegenerative disorder characterized not only by the hallmark patholo
entities	{'genes': ['MCI'], 'diseases': ["Alzheimer's Disease"], 'pathways': ['neuroinflammation', 'myelination', 'neuronal loss']}
model_system	human postmortem brain tissue (middle temporal gyrus)
_schema_version	1
experiment_type	clinical
primary_outcome	cellular population changes across AD progression phases
methodology_notes	## PROTOCOL Phase 1: Pre-intervention Characterization and Baseline Assessment (Weeks -4 to 0) Recruit a cohort of 48 transgenic AD model mice (APP/PS1 or 5xFAD line, 5-6 months old, n=24 interv
replication_status	replicated
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.896477', 'needs_review': False, 'extraction_notes': 'Backfilled from wiki source via PMID 39402379', 'extraction_confidence': 0.95}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

522

Outgoing

454

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Brain Connectivity-Targeted tACS Trial in Early AD

derives from (16)

supports (5)

💬 Discussion